Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

ATTD: Advanced Technologies and Treatments for Diabetes

Continuous Glucose Monitoring (CGM) in Type 2 Diabetes, ATTD 2025 Conference Catch-Up

20 Mar 2025

Description

In this episode of ATTD 2025 Conference Catch-Up, we dive into Continuous Glucose Monitoring (CGM) in Type 2 Diabetes, featuring discussions on the impact of CGM on glycemic control, cost-effectiveness, and its integration with lifestyle interventions and medications for improved diabetes management. Join us as we summarize key takeaways from these thought-provoking presentations: Real World Data on CGM in Type 2 Diabetes - Glucose Control Improvement – Dr. Richard Bergenstal Glycemic Excursion Minimization (GEM): A Lifestyle Intervention for the Management of Type 2 Diabetes – Prof. Chiara Fabris Cost Benefits of CGM Use in Type 2 Diabetes – Dr. Roy Beck CGM-Based Intensification and De-Intensification of Therapy in Type 2 Diabetes – Prof. Irl Hirsch This episode is an essential listen for endocrinologists, diabetes specialists, and healthcare professionals focused on Type 2 diabetes management, looking to learn more about the role of CGM in optimizing treatment plans, improving glycemic control, and managing healthcare costs. Enjoy the listen! This podcast was created using AI to provide a quick and insightful summary of ATTD 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.  ATTD 2025, the 18th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on March 19-22, 2025, in Amsterdam. https://attd.kenes.com

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.